Back to results
US 12,673,046 B2Granted
Substituted tetrazoles as ACSS2 inhibitors
AssigneesMerck Patent GmbH, Ryvu Therapeutics S.A.
InventorsThomas Fuchss, Lisa Koetzner, Christina Schindler, Daniel Kuhn
Life of this patent
Estimating the term…
Abstract
Substituted tetrazoles of formula I-a, I-b, or I-c: or a pharmaceutically acceptable salt, deuteroisotope, stereoisomer or tautomer thereof; useful as ACSS2 inhibitors are provided.
Claims26
A compound of formula (I-a), formula (I-b), or formula (I-c):
- or a pharmaceutically acceptable salt, deuteroisotope, stereoisomer, or tautomer thereof,
- wherein:
- R1 is ArA or HetarA;
- ArA is a monocyclic or bicyclic aryl;
- wherein the monocyclic or bicyclic aryl contains 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms;
- and
- wherein the monocyclic or bicyclic aryl is optionally substituted with one or more substituents independently selected from the group consisting of RA1, RA2, RA3, RA4, and RA5;
- HetarA is a monocyclic or bicyclic heteroaryl;
- wherein the monocyclic or bicyclic heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms;
- wherein the monocyclic or bicyclic heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms independently selected from the group consisting of N, O, and S;
- and
- wherein the monocyclic or bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RA1, RA2, RA3, RA4, and RA5;
- R2 is ArB or HetarB;
- ArB is a monocyclic or bicyclic aryl;
- wherein the monocyclic or bicyclic aryl contains 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms;
- and
- wherein the monocyclic or bicyclic aryl is optionally substituted with one or more substituents independently selected from the group consisting of RB1, RB2, RB3, RB4, and RB5;
- HetarB is a monocyclic or bicyclic heteroaryl;
- wherein the monocyclic or bicyclic heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms;
- wherein the monocyclic or bicyclic heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms independently selected from the group consisting of N, O, and S;
- and
- wherein the monocyclic or bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RB1, RB2, RB3, RB4, and RB5;
- each RA1 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA2 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA3 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA4 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA5 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB1 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB2 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB3 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB4 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB5 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- R3 is C1-6 aliphatic or OC1-6 aliphatic, wherein the C1-6 aliphatic or OC1-6 aliphatic is optionally substituted with one or more substituents independently selected from the group consisting of NH2 and OH;
- R4 is H, D, C1-6 aliphatic, or OC1-6 aliphatic;
- and
- R5 is H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic.
33 more elements
A compound of formula (II-a), formula (II-b), or formula (II-c):
- or a pharmaceutically acceptable salt, deuteroisotope, stereoisomer, or tautomer thereof,
- wherein:
- R1 is ArA or HetarA;
- ArA is a monocyclic or bicyclic aryl;
- wherein the monocyclic or bicyclic aryl contains 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms;
- and
- wherein the monocyclic or bicyclic aryl is optionally substituted with one or more substituents independently selected from the group consisting of RA1, RA2, RA3, RA4, and RA5;
- HetarA is a monocyclic or bicyclic heteroaryl;
- wherein the monocyclic or bicyclic heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms;
- wherein the monocyclic or bicyclic heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms independently selected from the group consisting of N, O, and S;
- and
- wherein the monocyclic or bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RA1, RA2, RA3, RA4, and RA5;
- R2 is ArB or HetarB;
- ArB is a monocyclic or bicyclic aryl;
- wherein the monocyclic or bicyclic aryl contains 5, 6, 7, 8, 9, 10, or 11 ring carbon atoms;
- and
- wherein the monocyclic or bicyclic aryl is optionally substituted with one or more substituents independently selected from the group consisting of RB1, RB2, RB3, RB4, and RB5;
- HetarB is a monocyclic or bicyclic heteroaryl;
- wherein the monocyclic or bicyclic heteroaryl contains 5, 6, 7, 8, 9, 10, or 11 ring atoms;
- wherein the monocyclic or bicyclic heteroaryl contains ring carbon atoms and 1, 2, 3, 4, or 5 ring heteroatoms independently selected from the group consisting of N, O, and S;
- and
- wherein the monocyclic or bicyclic heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of RB1, RB2, RB3, RB4, and RB5;
- each RA1 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA2 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA3 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA4 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RA5 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB1 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB2 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB3 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB4 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- each RB5 is independently H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic;
- R3 is C1-6 aliphatic or OC1-6 aliphatic, wherein the C1-6 aliphatic or OC1-6 aliphatic is optionally substituted with one or more substituents independently selected from the group consisting of NH2 and OH;
- R4 is H, D, C1-6 aliphatic, or OC1-6 aliphatic;
- and
- R5 is H, D, F, Cl, Br, I, C1-6 aliphatic, or OC1-6 aliphatic.
33 more elements
A compound selected from the group consisting of:
- or a pharmaceutically acceptable salt, deuteroisotope, stereoisomer, or tautomer thereof.
Dependencies are inferred from the claim text.